An advocacy group is suing the Trump administration for failing to disclose details of a settlement with Gilead over patent ...

With Black women and straight men increasingly at risk, Gilead’s Yeztugo may finally offer a discreet, stigma-free way to ...

Gilead Sciences, Inc. has announced that it has received new approval from the U.S. Food and Drug Administration (FDA) for a ...

Similarly, Gilead has provided nearly $35.8 million in total philanthropic support for Black women-led and/or Black ...

An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

"Gilead wins positive European approval opinion for twice-yearly HIV injection" was originally created and published by ...

Gilead upgraded to Buy by Needham as Yeztugo gains physician favor, with sales forecast to reach $6.4 billion by 2035, ...

Attorney General Dave Sunday announced that Pennsylvania will receive over $1 million as part of a $202 million multistate settlement with Gilead Sciences, Inc. over an illegal kickback scheme to ...

In one late-stage trial, 99.9% of patients who took Gilead's injection did not contract an infection. There were only two cases among more than 2,000 patients, effectively reducing the risk of HIV ...

Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to supply a long-acting HIV prevention drug to low-income countries, despite the ...

Gilead is prioritizing registering the drug in 18 countries with high HIV incidence rates, including Ethiopia, Kenya, Mozambique, Nigeria, Rwanda, South Africa, Uganda, Zimbabwe, Philippines ...

Gilead and the Global Fund will provide 2 million doses of its groundbreaking HIV prevention drug. Notably, the deal does not include PEPFAR.